Capricor Therapeutics, Inc.

NASDAQ:CAPR

5.12 (USD) • At close September 18, 2024
Bedrijfsnaam Capricor Therapeutics, Inc.
Symbool CAPR
Munteenheid USD
Prijs 5.12
Beurswaarde 166,599,168
Dividendpercentage 0%
52-weken bereik 2.68 - 7.28
Industrie Biotechnology
Sector Healthcare
CEO Dr. Linda Marbán Ph.D.
Website https://www.capricor.com

An error occurred while fetching data.

Over Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with

Vergelijkbare Aandelen

Tabula Rasa HealthCare, Inc. logo

Tabula Rasa HealthCare, Inc.

TRHC

10.5 USD

Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc.

LUCD

0.832 USD

Cytosorbents Corporation logo

Cytosorbents Corporation

CTSO

1.42 USD

Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc.

XLO

0.815 USD

Adverum Biotechnologies, Inc. logo

Adverum Biotechnologies, Inc.

ADVM

6.99 USD

Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc.

ALZN

1.73 USD

HOOKIPA Pharma Inc. logo

HOOKIPA Pharma Inc.

HOOK

4.62 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)